Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Mai 2016 03:00 ET | Quelle: Pluri Inc.

Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

HAIFA, Israel, May 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial...
09. Mai 2016 05:00 ET | Quelle: Pluri Inc.

Pluristem Awarded $3.3 Million Grant by Israeli Government

HAIFA, Israel, May 09, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its wholly...
21. April 2016 04:00 ET | Quelle: Pluri Inc.

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

HAIFA, Israel, April 21, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has...
13. April 2016 03:00 ET | Quelle: Pluri Inc.

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents

HAIFA, Israel, April 13, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the Japan...
16. Februar 2016 08:00 ET | Quelle: Pluri Inc.

National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

HAIFA, Israel, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the...
10. Februar 2016 08:00 ET | Quelle: Pluri Inc.

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

HAIFA, Israel, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial...
26. Januar 2016 03:00 ET | Quelle: Pluri Inc.

Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016

HAIFA, Israel, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Dr. Karine...
12. Januar 2016 03:00 ET | Quelle: Pluri Inc.

Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant

Phase I, open-label trial will allow for interim data analysisPLX-R18 could potentially treat a broad range of hematologic indications Pluristem will pursue early market access for PLX-R18 in the...
06. Januar 2016 05:00 ET | Quelle: Pluri Inc.

New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells

- First published study comparing therapeutic outcome of placenta-derived cells as compared to cells derived from bone marrow or fat tissue - Data describes the mechanism of action of PLX-PAD cells...
31. Dezember 2015 07:00 ET | Quelle: Pluri Inc.

U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem’s PLX-PAD Cells for Treatment of Severe Preeclampsia

HAIFA, Israel, Dec. 31, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the U.S....

Vorherige Seite

Nächste Seite